ArticleEuropean heart journal. Acute cardiovascular care2026
Impact of switching high-sensitivity cardiac troponin assays on risk stratification in suspected acute coronary syndrome.
Article in European heart journal. Acute cardiovascular care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
aimsCardiac troponin is central to risk stratification in patients with suspected acute coronary syndrome. High-sensitivity assays measuring cardiac troponin (hs-cTn) I or T are recommended by international guidelines. However, diagnostic thresholds for these assays are derived from different populations. We aimed to evaluate whether the change in assay influenced risk stratification. METHODS AND
resultsThis is a secondary analysis of the TWITCH-ED study enrolling 25 849 patients with suspected acute coronary syndrome between October 2020 and October 2022. In October 2021, sites changed from an hs-cTnI to an hs-cTnT assay. Study outcomes included discharge from the Emergency Department following a single cardiac troponin measurement, a composite outcome of subsequent myocardial infarction, heart failure hospitalization, or cardiovascular death at 1 year, and all-cause death at 1 year. Patients were stratified as low-risk at presentation using established thresholds. Higher proportions of patients were identified as low-risk (57.3% vs. 17.6%) and discharged following a single troponin measurement (47% vs. 30%) using the hs-cTnI assay, compared to the hs-cTnT assay (P < 0.001 for both). Those identified as low-risk with the hs-cTnT assay were younger (median 52 [inter-quartile range 40-62] vs. 41 [32-51] years) with fewer comorbidities, and had lower rates for the composite outcome (0.8% vs. 0.2%) and all-cause death (2.0% vs. 0.3%) (P < 0.001 for both) at 1 year.
conclusionRisk stratification thresholds for hs-cTnI and hs-cTnT assays do not provide equivalent performance. The hs-cTnT assay and threshold identified fewer low-risk patients suitable for discharge, with fewer subsequent cardiovascular events at 1 year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.